Posted by Michael Wonder on 25 Sep 2017
BioCryst's Rapivab (peramivir injection) receives FDA approval for a paediatric indication
21 September 2017 - BioCryst Pharmaceuticals announced today that the U.S. FDA has approved a supplemental new drug application for Rapivab (peramivir injection), an intravenous neuraminidase inhibitor, extending its availability for the treatment of acute uncomplicated influenza to paediatric patients two years and older who have been symptomatic for no more than two days.
The paediatric approval was based on the interim analysis of an ongoing paediatric clinical study. Those results will be presented at the upcoming ID Week 2017 meeting in San Diego.
